VOYAGER THERAPEUTICS INC. - COMMON STOCK

Voyager Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

22 Sep 2022 16:01:00 By Nasdaq GlobeNewswire

Voyager Therapeutics Appoints Peter Pfreundschuh as CFO; Todd Carter, Ph.D., as Chief Scientific Officer; and Trista Morrison as SVP Corporate Affairs

07 Sep 2022 07:30:00 By Nasdaq GlobeNewswire

Voyager Therapeutics Prioritizes Pipeline and Reports Second Quarter 2022 Financial and Operating Results

04 Aug 2022 16:01:00 By Nasdaq GlobeNewswire

Voyager Therapeutics Presents New Data Demonstrating Novel Candidate Therapeutic Antibodies Reduced Tau Pathology in Multiple Preclinical Models

03 Aug 2022 11:30:00 By Nasdaq GlobeNewswire

Voyager Therapeutics to Present Second Quarter 2022 Results and Corporate Update

02 Aug 2022 16:01:00 By Nasdaq GlobeNewswire

Voyager Therapeutics Appoints Catherine J. Mackey, Ph.D. to its Board of Directors

28 Jul 2022 07:00:01 By Nasdaq GlobeNewswire

Voyager Therapeutics’ TRACER™ Capsids Demonstrate Enhanced CNS Transduction Across Species; New Preclinical Results Bolster GBA1, Tau, SOD1 ALS Gene Therapy Programs

19 May 2022 06:00:00 By Nasdaq GlobeNewswire

Voyager Therapeutics to Present Preclinical Data from its Vectorized anti-HER2 Antibody Program and a Novel AAV5-Derived TRACER™ Capsid at the 25th American Society of Gene and Cell Therapy Annual Meeting

16 May 2022 06:00:00 By Nasdaq GlobeNewswire

Voyager Therapeutics Reports First Quarter 2022 Financial and Operating Results

04 May 2022 16:01:01 By Nasdaq GlobeNewswire

Voyager Therapeutics Announces Multiple Data Presentations at the American Society of Gene and Cell Therapy 2022 Annual Meeting

03 May 2022 07:00:01 By Nasdaq GlobeNewswire

Voyager Therapeutics Appoints Alfred W. Sandrock, Jr., M.D., Ph.D., as Chief Executive Officer

22 Mar 2022 07:00:01 By Nasdaq GlobeNewswire

Voyager Therapeutics Reports Fourth Quarter and Full Year 2021 Financial and Operating Results

08 Mar 2022 06:16:21 By Nasdaq GlobeNewswire

Voyager Therapeutics Announces License Option Agreement with Novartis for Target-Specific Access to Next-Generation TRACER™ AAV Capsids for Gene Therapy Programs

08 Mar 2022 01:15:00 By Nasdaq GlobeNewswire

Voyager Therapeutics to Participate in Upcoming Investor Conferences

10 Feb 2022 07:00:01 By Nasdaq GlobeNewswire

Alfred W. Sandrock, Jr., M.D., Ph.D. Appointed to Voyager Therapeutics’ Board of Directors and Newly Formed Executive Committee

03 Feb 2022 07:00:01 By Nasdaq GlobeNewswire

Voyager Therapeutics Announces Positive Preclinical Data from New Vectorized anti-HER2 Antibody Program at the 26th Society for Neuro-Oncology Annual Meeting

19 Nov 2021 07:30:00 By Nasdaq GlobeNewswire

Voyager Therapeutics to Present Preclinical Data from Vectorized Antibody Program at the 26th Society for Neuro-Oncology Annual Meeting

16 Nov 2021 07:00:01 By Nasdaq GlobeNewswire

Voyager Therapeutics Reports Third Quarter 2021 Financial and Operating Results

02 Nov 2021 07:00:02 By Nasdaq GlobeNewswire

Voyager Therapeutics Presents Positive Preclinical Data Supporting CNS-Directed GBA1 Gene Therapy at Virtual Congress of the European Society of Gene and Cell Therapy

20 Oct 2021 08:54:43 By Nasdaq GlobeNewswire

Voyager Therapeutics Announces License Option Agreement with Pfizer for Next-Generation TRACERᵀᴹ AAV Capsids to Enable Neurologic and Cardiovascular Gene Therapy Programs

06 Oct 2021 07:00:00 By Nasdaq GlobeNewswire